These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. Bai L; Chen J; McEachern D; Liu L; Zhou H; Aguilar A; Wang S PLoS One; 2014; 9(6):e99404. PubMed ID: 24901320 [TBL] [Abstract][Full Text] [Related]
23. TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo. Karpel-Massler G; Bâ M; Shu C; Halatsch ME; Westhoff MA; Bruce JN; Canoll P; Siegelin MD Oncotarget; 2015 Nov; 6(34):36456-71. PubMed ID: 26474387 [TBL] [Abstract][Full Text] [Related]
24. Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs. Bricelj A; Dora Ng YL; Gobec M; Kuchta R; Hu W; Javornik Š; Rožič M; Gütschow M; Zheng G; Krönke J; Steinebach C; Sosič I Chemistry; 2024 Aug; 30(45):e202400430. PubMed ID: 38818652 [TBL] [Abstract][Full Text] [Related]
25. Co-targeting BCL-X Khan S; Kellish P; Connis N; Thummuri D; Wiegand J; Zhang P; Zhang X; Budamagunta V; Hua N; Yang Y; De U; Jin L; Zhang W; Zheng G; Hromas R; Hann C; Zajac-Kaye M; Kaye FJ; Zhou D Cell Death Discov; 2023 Jan; 9(1):1. PubMed ID: 36588105 [TBL] [Abstract][Full Text] [Related]
26. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X Zhang X; Thummuri D; He Y; Liu X; Zhang P; Zhou D; Zheng G Chem Commun (Camb); 2019 Dec; 55(98):14765-14768. PubMed ID: 31754664 [TBL] [Abstract][Full Text] [Related]
27. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Zhang M; Mathews Griner LA; Ju W; Duveau DY; Guha R; Petrus MN; Wen B; Maeda M; Shinn P; Ferrer M; Conlon KD; Bamford RN; O'Shea JJ; Thomas CJ; Waldmann TA Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12480-5. PubMed ID: 26396258 [TBL] [Abstract][Full Text] [Related]
34. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC). Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779 [TBL] [Abstract][Full Text] [Related]
35. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046 [TBL] [Abstract][Full Text] [Related]
36. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors. Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567 [TBL] [Abstract][Full Text] [Related]
37. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766 [TBL] [Abstract][Full Text] [Related]
38. Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. Punnoose EA; Leverson JD; Peale F; Boghaert ER; Belmont LD; Tan N; Young A; Mitten M; Ingalla E; Darbonne WC; Oleksijew A; Tapang P; Yue P; Oeh J; Lee L; Maiga S; Fairbrother WJ; Amiot M; Souers AJ; Sampath D Mol Cancer Ther; 2016 May; 15(5):1132-44. PubMed ID: 26939706 [TBL] [Abstract][Full Text] [Related]
39. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357 [TBL] [Abstract][Full Text] [Related]
40. Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma. Zhang Y; Ishida CT; Shu C; Kleiner G; Sanchez-Quintero MJ; Bianchetti E; Quinzii CM; Westhoff MA; Karpel-Massler G; Siegelin MD Sci Rep; 2018 May; 8(1):7373. PubMed ID: 29743557 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]